Details

Autor(en) / Beteiligte

• Bhatt, Deepak L., MD, FACC
• Flather, Marcus D., MD
• Hacke, Werner, MD
• Berger, Peter B., MD, FACC
• Black, Henry R., MD
• Boden, William E., MD, FACC
• Cacoub, Patrice, MD
• Cohen, Eric A., MD
• Creager, Mark A., MD, FACC
• Easton, J. Donald, MD
• Hamm, Christian W., MD, FACC
• Hankey, Graeme J., MD
• Johnston, S. Claiborne, MD, PhD
• Mak, Koon-Hou, MD, FACC
• Mas, Jean-Louis, MD
• Montalescot, Gilles, MD, PhD
• Pearson, Thomas A., MD, FACC
• Steg, P. Gabriel, MD, FACC
• Steinhubl, Steven R., MD, FACC
• Weber, Michael A., MD, FACC
• Fabry-Ribaudo, Liz, MSN, RN
• Hu, Tingfei, MS
• Topol, Eric J., MD, FACC
• Fox, Keith A.A., MBChB

Titel

Patients With Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA Trial

Ist Teil von

• Journal of the American College of Cardiology, 2007-05, Vol.49 (19), p.1982-1988

Ort / Verlag

New York, NY: Elsevier Inc

Erscheinungsjahr

2007

Quelle

MEDLINE

Beschreibungen/Notizen

• Patients With Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA Trial Deepak L. Bhatt, MD, FACC, Marcus D. Flather, MD, Werner Hacke, MD, Peter B. Berger, MD, FACC, Henry R. Black, MD, William E. Boden, MD, FACC, Patrice Cacoub, MD, Eric A. Cohen, MD, Mark A. Creager, MD, FACC, J. Donald Easton, MD, Christian W. Hamm, MD, FACC, Graeme J. Hankey, MD, S. Claiborne Johnston, PhD, MD, Koon-Hou Mak, MD, FACC, Jean-Louis Mas, MD, Gilles Montalescot, MD, PhD, Thomas A. Pearson, MD, FACC, P. Gabriel Steg, MD, FACC, Steven R. Steinhubl, MD, FACC, Michael A. Weber, MD, FACC, Liz Fabry-Ribaudo, MSN, RN, Tingfei Hu, MS, Eric J. Topol, MD, FACC, Keith A. A. Fox, MBChB, for the CHARISMA Investigators Dual antiplatelet therapy with clopidogrel plus aspirin has already been validated in the settings of acute coronary syndromes and coronary stenting. We identified 9,478 patients in the CHARISMA (Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance) trial who were enrolled with documented prior myocardial infarction (MI), ischemic stroke, or symptomatic peripheral arterial disease. The median duration of follow-up was 27.6 months. The rate of cardiovascular death, MI, or stroke was significantly lower in the clopidogrel plus aspirin arm than in the placebo plus aspirin arm: 7.3% versus 8.8% (hazard ratio 0.83, 95% confidence interval 0.72 to 0.96, p = 0.01); this benefit persisted after multivariate modeling and was not dependent on the time from the ischemic event.